| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.025 | 0.4 |